China's medical products administrator approved Chongqing Genrix Biopharmaceutical's (SHA:688443) clinical trial for its GR1803 injection for systemic lupus erythematosus, according to a Thursday filing with the Shanghai bourse.
The drug helps treat the systemic autoimmune disease, the filing said.
GR1803 is undergoing phase 2 trials for relapsed/refractory multiple myeloma, a type of blood cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments